Comparison of Hounsfield Units and Vertebral Bone Quality Score for the Prediction of Time to Pathologic Fracture in Mobile Spine Metastases Treated With Radiotherapy
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Cummings S, Ferrari S, Eastell R, Gilchrist N, Jensen J, McClung M
. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. J Bone Miner Res. 2017; 33(2):190-198.
DOI: 10.1002/jbmr.3337.
View
2.
Symonds C, Kline G
. Warning of an increased risk of vertebral fracture after stopping denosumab. CMAJ. 2018; 190(16):E485-E486.
PMC: 5915244.
DOI: 10.1503/cmaj.180115.
View
3.
Patel P, Esposito E, Zhu J, Chen X, Khan M, Kleinberg L
. Antiresorptive Medications Prior to Stereotactic Body Radiotherapy for Spinal Metastasis are Associated with Reduced Incidence of Vertebral Body Compression Fracture. Global Spine J. 2023; 14(6):1778-1785.
PMC: 11268289.
DOI: 10.1177/21925682231156394.
View
4.
Henry D, Vadhan-Raj S, Hirsh V, Von Moos R, Hungria V, Costa L
. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2013; 22(3):679-87.
DOI: 10.1007/s00520-013-2022-1.
View
5.
Bone H, Wagman R, Brandi M, Brown J, Chapurlat R, Cummings S
. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017; 5(7):513-523.
DOI: 10.1016/S2213-8587(17)30138-9.
View